Changing the future of Oncology.
Clinical/Scientific Presentation and Publication Highlights
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Poster
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian Cancer Download Poster, CLICK HERE
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian CancerDownload Presentation, CLICK HERE
Jefferies Virtual Healthcare Conference 2021 – Presentation
Webcast, Click Here Download Presentation, Click Here
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – STRO-002 – Abstract
To view the abstract on ASCO, click here
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR and nine patients achieved a PR, of which four were confirmed PRs. Median duration of response on the five confirmed...
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
7th Annual Truist Securities Life Sciences Summit – Presentation
Webcast, Click Here Download Presentation, Click Here
20th Annual Needham Virtual Healthcare Conference – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation
Download the presentation, CLICK HERE